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 Editorial
In this edition of the journal, Drs Kisten and Biccard have published an 
interesting article evaluating the incidence and in-hospital mortality 
among patients suffering a perioperative myocardial infarction (PMI) 
and myocardial injury after noncardiac surgery (MINS) in a retrospective 
cohort of 140 vascular surgery patients admitted to an intensive care 
unit (ICU) after surgery.1 The authors defined PMI based on the Third 
Universal Definition of Myocardial Infarction2 and used a Siemens 
troponin I threshold of ≥ 600 ng/L and MINS based on a troponin I of 
41 to 599 ng/L that was adjudicated as resulting from an ischaemic 
aetiology.  PMI occurred in 34 patients (24.3%) and MINS in 35 patients 
(25.0%). The incidence of in-hospital mortality among patients who did 
not suffer PMI or MINS, had MINS, and had PMI was 18.3%, 20.0%, and 
58.8% respectively. A multivariable model that included PMI, MINS, and 
postoperative brain natriuretic peptide demonstrated that only PMI was 
associated with in-hospital mortality (odds ratio, 4.3; 95% confidence 
interval [CI], 1.4–12.9).1 
This study provides important information highlighting the impact of 
PMI in South African vascular surgery patients admitted directly to an 
ICU.  Before dismissing MINS that did not fulfill the diagnostic criteria for 
PMI, several points are worth considering. 
The VISION study was a large, international, prospective cohort that 
included a representative sample of patients ≥  45 years of age who 
underwent in-patient noncardiac surgery.3 In contrast to the findings 
in the current study, in analyses of 15  065 patients, the VISION Study 
demonstrated that a MINS event that did not fulfill the Universal 
Definition of MI was independently associated with 30-day mortality 
(adjusted hazard ratio [HR], 3.3; 95% CI, 2.3–4.8).4 Moreover, these 
VISION analyses included patients from South Africa, and the frailty 
model suggested the results were consistent across study centres. 
A substudy focused on the 502 vascular surgery VISION patients 
demonstrated a 30-day mortality rate of 12.5% (95% CI, 7.3–20.6%) 
and 1.5% (95% CI, 0.7–3.2%) in patients who suffered and did not suffer 
MINS, respectively.5 MINS was independently associated with mortality 
(adjusted odds ratio [OR], 9.5; 95% CI, 3.5–26.0). The 30-day mortality 
was similar in MINS patients who did (15.0%; 95% CI, 7.1–29.1) and did 
not (12.2%; 95% CI, 5.3–25.5, p=0.76) fulfill the Universal Definition of 
Myocardial Infarction, and the proportion of vascular surgery patients 
who suffered MINS without overt evidence of myocardial ischemia was 
74.1% (95% CI, 63.6–82.4).
In the current study,1 the authors used a troponin I assay for which MINS 
thresholds have not been established. Recently, 5th generation high-
sensitivity troponin T (hsTnT) thresholds independently associated with 
30-day mortality were identified through iterative cox proportional 
hazards models from 21  842 patients in the VISION Study.6 Based on 
these analyses, VISION investigators defined MINS as an hsTnT > 20 ng/L 
and < 65 ng/L with a change of > 5 ng/L or hsTnT ≥ 65 ng/L within 30-
days after surgery that was adjudicated as resulting from an ischemic 
etiology. The thresholds determined by these analyses are higher than 
the 99th percentile of URL for the hsTnT assay (14 ng/L).  This publication 
highlights the importance of determining the threshold for each 
troponin assay in the perioperative setting because the 99th percentile 
threshold proposed by the Third definition of MI may not apply in the 
perioperative setting. It is possible that the Siemens TnI thresholds, used 
by the authors of the current study to define MINS, were suboptimal. 
The VISION investigators have also shown that the higher the troponin 
threshold the stronger the association to death.6 It is therefore possible 
in the current study of 140 patients that the authors simply did not 
have enough power to establish the association between their MINS 
diagnostic criteria and in-hospital mortality. 
Although at present there are no published randomized controlled trials 
informing treatment effects of interventions in patients suffering MINS, 
perioperative observational studies suggest that secondary prevention 
cardiovascular treatments appear to have benefit. One French study 
showed that MINS patients who received cardiovascular treatment 
optimization based on aspirin, statin, angiotensin-converting enzyme 
inhibitor and beta-blocker had similar outcomes to perioperative 
patients who did not suffer MINS (HR, 0.6; 95% CI, 0.1–1.2; p=0.45); 
however, patients who suffered MINS who did not receive or have 
intensified one or more of these cardiovascular medications had a 
worse 1 year major cardiovascular outcome than patients who did not 
suffer MINS (2.8; 95% CI, 1.1–24.2; p= 0.04).7 Similarly in the POISE Trial, 
multivariable regression analysis suggested that among patients who 
had a perioperative myocardial infarction acetylsalicylic acid and statin 
use were associated with a reduction in the risk for 30-day mortality 
(adjusted ORs, 0.54; 95% CI, 0.29–0.99 and 0.26; 95% CI, 0.13–0.54 
respectively).8 Based on these findings the recently published Canadian 
Perioperative Guidelines strongly recommends the initiation of long-
term aspirin and statin for patients who suffer MINS.9 
Considering the totality of data, MINS events that do not fulfill the 
Universal Definition of Myocardial Infarction appear to have important 
prognostic implications for patients. The VISION vascular surgery 
substudy suggests these results also apply to vascular surgery patients.5 
Further studies like the one by Drs Kisten and Biccard1 are needed to 
better understand MINS in South Africa and the African continent. 
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